See feature article below: Pulmatrix, Inc. (NASDAQ: PULM)
Broad Street Alerts recent profiles and track record, 642% in verifiable potential gains for our members on 3 recent small cap alerts alone!
May 9th, 2016-(NYSE-MKT: MGT) opened at .64/share and hit over $4.15/share within 8 days for potential gains of 548% for our members.
May 23rd, 2016 (NYSE-MKT: XXII) opened at $.78/share and hit $.94/share within 2 days for potential gains of 20% for our members.
May 26th, 2016 (NASDAQ: CETX) opened at $2.00/share and hit $3.50/share within 10 days for potential gains of 74% for our members.
***Get our small cap profiles, special situation and watch alerts in real time. We are now offering our VIP SMS/text alert service for free, simply text the word “Alerts” to the phone number 25827 from your cell phone.
Report For: Pulmatrix, Inc. (NASDAQ: PULM)
PHILADELPHIA, PA / ACCESSWIRE / June 13, 2016 / CEOCFO Magazine, an independent investment and B2B publication that conducts interviews with company CEOs, announced today that it has published an interview with Robert Clarke, PhD, CEO of Pulmatrix, Inc. (PULM).
As Dr. Clarke describes in the interview, Pulmatrix is a small pharmaceutical company developing innovative inhaled drugs to treat respiratory diseases. “Specifically, we look at COPD, asthma, cystic fibrosis, and idiopathic pulmonary fibrosis, all of which are major diseases of the lung,” Dr. Clarke says.
Pulmatrix has created a novel engineered dry powder technology, called iSPERSE™, for delivering drugs deep into the lungs. “What differentiates it from traditional inhaled approaches is that the particles fly very easily into the patients’ airways,” Dr. Clarke explains. That boosts the efficiency of drug delivery and makes it possible to deliver high doses when needed.
The first product candidate in the company’s pipeline is PUR0200, a once daily bronchodilator for chronic obstructive pulmonary disease (COPD), which affects tens of millions of patients worldwide. Clinical data show that Pulmatrix’s delivery system is so efficient that PUR0200 can use a dose of the active drug that’s 80% lower than that of the current standard of care to get similar benefits. Pulmatrix expects to follow a quick path to approval in Europe, while also seeking approval in the U.S.
The next product candidate is PUR1900, an inhaled drug to treat fungal infections in the airways of patients. The only current treatment, using oral antifungal drugs, is both relatively ineffective and causes serious side effects. That’s because “you have to take a lot of the antifungal orally to get the drug into the bloodstream and all the way into the lung tissue,” Dr. Clarke explains. “We believe we can correct both of those issues.”
The iSPERSE technology can deliver virtually any type of drug, from small molecules to large antibodies, so it can be used for many different diseases. “We have this applicable technology to bring better products forward for patients,” says Dr. Clarke. The company now is considering other disease targets. It also has a strong financial position, having raised enough money last year “to take us into mid-2017,” says Dr. Clarke. The Pulmatrix CEO discussed the company’s plans in a recent Stock-Sector.com news interview. http://stock-sector.com/stock-sector-discusses-pulmatrixs-unique-inhaled-drugs-in-interview-with-ceo-dr-robert-clarke/.
Source – Company Press Release
DISCLAIMER
Broadstreetalerts.com is a wholly owned subsidiary of Small Cap Specialists LLC, herein referred to as SCS LLC.
Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use.
PLEASE NOTE WELL: SCS LLC and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.
Release of Liability: Through use of this website viewing or using you agree to hold SCS LLC, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. SCS LLC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and SCS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead SCS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. SCS LLC is compliant with the Can Spam Act of 2003. SCS LLC does not offer such advice or analysis, and SCS LLC further urges you to consult your own independent tax, business, financial and investment advisors. SCS LLC has been compensated twenty thousand dollars cash via bank wire by star media llc for a two day investor relations campaign of STEM. SCS LLC does not hold any positions in STEM. SCS LLC has previously been compensated twenty thousand dollars cash via bank wire by DF Media for the mention of MGT. We do not hold any positions in MGT. Investing in micro-cap and growth securities is highly speculative and carries and extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled. We have not been compensated nor do we own positions in the company/companies that are in the featured article.
The Private Securities Litigation Reform Act of 1995 provides investors a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be “forward looking statements”. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions & quote; “may”, “could”, or “might” occur. Understand there is no guarantee past performance will be indicative of future results.
In preparing this publication, SCS LLC has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this website are believed to be reliable, however, SCS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. SCS LLC is not responsible for any claims made by the companies advertised herein, nor is SCS LLC responsible for any other promotional firm, its program or its structure.
Please Note: We do NOT accept free trading or restricted securities as payment for our services.
SCS LLC is not affiliated with any exchange, electronic quotation system, the Securities Exchange Commission or FINRA. SCS LLC is not a Broker/Dealer and does not engage in high frequency trading.
Stock market
Hot small cap stocks
small cap stock picks
Biotech stocks
FDA approval stocks
FDA calendar
Trade stocks
Become a day trader
Day trade stocks for a living
PDUFA date set
micro cap stocks
Best stocks 2016
Hottest small cap stocks
Best stock picks
Who to follow for stock picks
Apple news stock picks
Stock picks on apple news
